Receptor Pharmacology 101: How Peptides Actually Work

Peptides occupy an unusual niche in pharmacology. They are large enough to carry the binding specificity of a protein, small enough to be synthesized on a solid-phase resin, and fragile enough to be broken down by the same enzymes that digest a meal. Understanding why a peptide works the way it does — why it binds one receptor and not another, why its effect fades over hours rather than days, why it almost never survives oral administration — requires a short tour through receptor pharmacology.

What a receptor actually is

A receptor is a protein, usually embedded in a cell membrane, whose three-dimensional shape includes a pocket or surface that matches a specific molecule. When the matching molecule — the ligand — occupies that pocket, the receptor changes shape. That shape change is the signal. Everything downstream, from a second messenger cascade to a change in gene expression, depends on that initial fit.

Receptors are sorted into families by how they transduce that signal. Ion channels open a pore. Kinase-linked receptors phosphorylate intracellular targets. Nuclear receptors, which sit inside the cell rather than on its surface, bind DNA directly. The family that dominates peptide pharmacology, however, is the G-protein-coupled receptor family, or GPCR. Roughly a third of all approved drugs target a GPCR of some kind, and most endogenous peptide hormones — insulin and growth hormone being notable exceptions — signal through them.

A GPCR threads through the cell membrane seven times, forming a bundle of transmembrane helices. The ligand-binding site is typically on the extracellular side. The intracellular side is coupled to a heterotrimeric G-protein. When the ligand binds, the helices rearrange, the G-protein dissociates into its alpha and beta-gamma subunits, and those subunits go on to activate or inhibit downstream effectors such as adenylyl cyclase or phospholipase C. The cascade amplifies: one activated receptor can cycle through many G-proteins before it resets.

Agonists, antagonists, and everything between

Not every molecule that fits a receptor pocket activates it. Pharmacologists distinguish between several behaviors, and the distinctions matter for how a peptide is classified.

A full agonist binds and produces the maximum response the receptor can generate. The endogenous ligand is usually, though not always, a full agonist at its own receptor. A partial agonist binds and produces a submaximal response even at saturating concentrations — it occupies the pocket but only partially induces the conformational change. An antagonist binds without activating; it occupies the pocket and prevents an agonist from doing anything. An inverse agonist, a subtler category, reduces the receptor's baseline activity below its unliganded resting state, which matters for receptors that have constitutive signaling.

Peptides in research contexts span every one of these categories. GHRP-6 and Ipamorelin are agonists at the ghrelin receptor. Semaglutide and Tirzepatide are agonists at GLP-1 (and in the case of Tirzepatide, at GIP as well). Retatrutide adds a third agonist arm at the glucagon receptor. Some experimental compounds in the melanocortin family behave as antagonists at MC4R and agonists at MC1R depending on the isoform. The same chemical backbone can act differently at different receptors within the same family, which is why selectivity profiles matter more than potency numbers in isolation.

Binding affinity, potency, and efficacy

Three numbers tend to show up in any serious pharmacology paper, and they are not interchangeable.

The dissociation constant, or Kd, describes how tightly a ligand binds its receptor. It is measured in units of concentration — typically nanomolar or picomolar for peptide hormones — and a lower Kd means tighter binding. Formally, Kd is the concentration at which half the receptors are occupied at equilibrium. A Kd of 1 nM means that at 1 nM free ligand, half the receptor pool is bound. This is a pure binding measurement. It says nothing about whether the bound receptor does anything.

EC50 is a functional measurement. It is the concentration of ligand that produces half the maximum biological response in a given assay — cAMP accumulation, calcium flux, beta-arrestin recruitment, or whatever readout the assay uses. EC50 depends on the assay, the cell line, the receptor density, and the coupling efficiency, so EC50 values across different papers are not directly comparable. Kd and EC50 often differ by an order of magnitude or more, and that gap is informative: it reflects receptor reserve, signal amplification, and whether the ligand is a full or partial agonist.

Efficacy, sometimes called intrinsic activity, is the maximum response a ligand can produce relative to a reference full agonist at the same receptor. A partial agonist might have an excellent Kd and a low EC50 but a ceiling of only 40 or 50 percent of full response. In reported studies, that ceiling matters for long-term signaling because partial agonists often desensitize receptors less aggressively than full agonists.

Why peptides are so specific — and so short-acting

A small molecule drug — aspirin, caffeine, a beta-blocker — typically makes contact with a receptor through a handful of atoms. Specificity comes from the precise geometry of those few contacts. A peptide of 10 to 40 amino acids, by contrast, drapes across a much larger surface area. The binding interface can involve dozens of hydrogen bonds, salt bridges, and hydrophobic contacts distributed along the length of the peptide. That is the structural reason peptides tend to be exquisitely selective for their cognate receptors: there is simply more surface over which to discriminate.

The same property that makes peptides specific also makes them fragile. A peptide is, by definition, a chain of amino acids connected by peptide bonds. Those bonds are the substrates of a large family of enzymes called peptidases, or proteases, which exist throughout the body — in the gut, the blood, the liver, the kidneys, and inside cells. A native peptide introduced into circulation is typically degraded within minutes. GLP-1, for instance, has a half-life in human plasma of roughly two minutes before DPP-4 cleaves it at the second N-terminal residue. The entire strategy behind long-acting GLP-1 analogs such as Semaglutide is to modify the molecule — substituting a residue at the DPP-4 cleavage site, adding a fatty acid chain that binds albumin — to slow that degradation. The peptide's shape is preserved. Its resistance to enzymes is engineered in.

This has direct consequences for route of administration. Oral bioavailability of a native, unmodified peptide is, for practical purposes, near zero. The peptide encounters gastric acid, then pepsin in the stomach, then trypsin, chymotrypsin, and a dozen other enzymes in the small intestine. What little survives faces the intestinal wall, where brush-border peptidases degrade most of the remainder, and the peptide must then cross the epithelium and survive first-pass hepatic metabolism. Oral Semaglutide exists only because it is co-formulated with an absorption enhancer (SNAC) that transiently protects the peptide at the gastric mucosa, and even then bioavailability is on the order of one percent. For the overwhelming majority of peptides, the research route of administration is subcutaneous or intramuscular injection for the same reason insulin is injected: the oral route does not deliver a meaningful dose.

Receptor desensitization and downregulation

No receptor signals forever in the presence of its ligand. If it did, a single meal would leave insulin receptors firing for the rest of the day. Cells have evolved multiple mechanisms to turn the signal off, and these mechanisms are central to how peptide dosing schedules are designed in research.

The first layer is phosphorylation. Within seconds of GPCR activation, G-protein-coupled receptor kinases (GRKs) phosphorylate the intracellular tail of the receptor. That phosphorylation recruits beta-arrestin, which physically blocks further G-protein coupling. The receptor is still on the cell surface and still binds ligand, but it no longer transduces a signal. This is desensitization, and it happens on a timescale of seconds to minutes.

The second layer is internalization. Beta-arrestin-bound receptors are pulled into the cell inside clathrin-coated vesicles. Once internalized, a receptor can either be dephosphorylated and recycled back to the surface (resensitization) or trafficked to lysosomes and degraded (downregulation). Which fate it meets depends on the receptor, the ligand, and the duration of exposure. Chronic agonist exposure — continuous high-dose administration over days to weeks — tends to favor degradation, and the total receptor population on the cell surface drops. The tissue becomes less responsive to the ligand. This is the molecular basis of pharmacological tolerance.

Desensitization explains several observations researchers encounter. Pulsatile administration of a peptide often produces different effects than continuous infusion of the same total dose. Growth hormone-releasing peptides, for example, are reported to drive larger GH pulses when dosed intermittently than when infused continuously, because continuous exposure desensitizes the ghrelin receptor and downstream GHRH signaling. Similarly, the cycling schedules commonly used in research protocols for melanocortin agonists are a practical response to MC4R downregulation observed in preclinical studies.

Biased agonism and the next layer of complexity

A simplifying assumption in classical pharmacology is that a GPCR is a binary switch: bound or unbound, on or off. That assumption is wrong in an interesting way. Modern structural and functional studies show that a receptor can adopt multiple active conformations, and different ligands can stabilize different ones. One conformation may couple efficiently to the G-protein pathway and poorly to beta-arrestin. Another may do the opposite. A ligand that preferentially activates one pathway over the other is called a biased agonist.

Biased agonism matters because the two pathways often produce different downstream effects. At the mu-opioid receptor, G-protein signaling is associated with analgesia while beta-arrestin recruitment is associated with respiratory depression and tolerance. The therapeutic interest in biased mu-opioid agonists reflects the hope of separating those outcomes. At peptide receptors, a similar story is emerging: some GLP-1 analogs appear to be biased toward cAMP signaling and away from beta-arrestin, which may explain differences in glycemic effect, gastric emptying, and receptor desensitization across the class.

Bias is measured by comparing the relative EC50 and efficacy of a ligand across two or more assays — cAMP versus beta-arrestin recruitment, for instance — and quantified as a bias factor. The concept is useful but fragile: bias factors can flip depending on the reference ligand, the cell line, and the assay conditions. In the current literature, biased agonism is best treated as a working hypothesis about mechanism rather than a settled property of a molecule.

What to read next

For a deeper mechanical treatment, the classic reference is Goodman and Gilman's Pharmacological Basis of Therapeutics, particularly the opening chapters on receptor theory. For structural biology of GPCRs specifically, the 2012 Nobel Prize lectures by Kobilka and Lefkowitz are freely available and remain the clearest short introduction to how a seven-transmembrane bundle actually moves when a ligand binds. For peptide-specific pharmacokinetics — half-life engineering, lipidation, PEGylation, and the tradeoffs involved — the review literature on GLP-1 analog development from 2018 onward is a practical starting point, because the engineering problems encountered there recur across most therapeutic and research peptide classes.